Pacira BioSciences

PCRX

Market cap $962M

-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods —

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on Wednesday, April 15, 2026.

-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from two real-world studies evaluating the economic benefits of EXPAREL® (bupivacaine liposome injectable suspension) in orthopaedic procedures, including total knee arthroplasty (TKA) and spinal fusion. In both studies, EXPAREL was associated with lower total cost of care compared with ropivacaine in one study and standard of care options (non-LB) in the other, with reductions observed in both outpatient and inpatient surgical settings. The data will be presented at the Orthopaedic Research Society (ORS) 2026 Annual Meeting taking place March 27–31 in Charlotte, North Carolina.

Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years [i] ; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30% [ii] ; The Company's Underperformance is Reflected in Consistently Missed Earnings, Continuous Lowering of Guidance, Which is Then Missed, and a Complete Lack of Combined Profitability in the Last Two Years [iii] ; We believe the Stock Price Reflects the Market's Lack of Trust in Management and the Board of Director's Utter Failure of Oversight DOMA Asserts Frank Lee Should be Replaced Immediately; the Board Should Name an Interim CEO and Conduct a Formal Sale Process of the Business DOMA's Three Highly Qualified Nominees Possess Vast Experience in Strategic Capital Allocation, Risk Management, Healthcare, Internal Investigations, Litigation, and Due Diligence MIAMI, March 12, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management LLC ("DOMA Perpetual") is a fundamentals-based, value-oriented investor that, together with its affiliates (collectively "DOMA" or "we"), beneficially owns approximately 7.3% of the outstanding shares of common stock of Pacira BioSciences (NASDAQ: PCRX) ("Pacira" or the "Company").[iv] DOMA today announced its nomination of three highly skilled director candidates to Pacira's Board of Directors (the "Board"): Christopher Dennis, Oliver Benton Curtis III and Eric de Armas.

-- Issues Statement in Response to DOMA's Nomination of Director Candidates --  -- No Shareholder Action Required at This Time --

Pacira BioSciences, Inc. (PCRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years i ; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30% ii ; The Company's Underperformance is Reflected in Consistently Missed Earnings, Continuous Lowering of Guidance, Which is Then Missed, and a Complete Lack of Combined Profitability in the Last Two Years iii ; We believe the Stock Price Reflects the Market's Lack of Trust in Management and the Board of Director's Utter Failure of Oversight DOMA Asserts Frank Lee Should be Replaced Immediately; the Board Should Name an Interim CEO and Conduct a Formal Sale Process of the Business DOMA's Three Highly Qualified Nominees Possess Vast Experience in Strategic Capital Allocation, Risk Management, Healthcare, Internal Investigations, Litigation, and Due Diligence MIAMI, March 11, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management LLC ("DOMA Perpetual") is a fundamentals-based, value-oriented investor that, together with its affiliates (collectively "DOMA" or "we"), beneficially owns approximately 7.1% of the outstanding shares of common stock of Pacira BioSciences (NASDAQ: PCRX) ("Pacira" or the "Company").iv DOMA today announced its nomination of three highly skilled director candidates to Pacira's Board of Directors (the "Board"): Christopher Dennis, Oliver Benton Curtis and Eric de Armas. DOMA believes electing these nominees is critical to address the Board's lack of financial controls, sophistication and legal expertise, and to develop proper management oversight at the Board level.

BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami.

PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.